ArticleMaterials (Basel, Switzerland)2026
Mechanism Research on Thieno-Fused Bis-BODIPY Bifunctional Photosensitizers.
Article in Materials (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study is dedicated to the development of novel boron-dipyrromethene (BODIPY)-based photosensitizers, focusing on investigating the regulatory mechanism of introducing different electron-donating groups at the α-position on the photosensitizing performance of thieno-bis-BODIPY derivatives, aiming to provide a theoretical basis for cancer photodynamic therapy (PDT). Five thieno-bis-BODIPY molecules (FD1-FD5) were constructed by connecting two BODIPY units via a thiophene π-bridge and introducing various substituents at the α-position of their phenyl groups. Systematic theoretical studies revealed that unilaterally substituted molecules exhibit superior photophysical properties compared to their bilaterally substituted counterparts. The key mechanisms involve structural planarization, increased electrostatic potential difference, and the formation of hybrid LE/CT characteristics in the excited state, all of which collectively promote the intersystem crossing (ISC) process. Specifically, the pyrrole-substituted FD4 exhibits the highest ISC efficiency due to its stronger electron-donating ability and greater molecular planarity, and it is predicted to possess a stronger singlet oxygen generation capability than the methoxy-substituted FD2 while maintaining fluorescence emission. In contrast, bilateral substitution leads to structural distortion, which favors fluorescence emission, as seen in FD5 which exhibits the longest absorption wavelength. This research elucidates the key mechanisms for enhancing ISC and photosensitizing performance from the perspectives of electronic structure and excited-state characteristics, providing theoretical guidance for overcoming limitations such as insufficient tissue penetration in traditional BODIPY photosensitizers and clarifying structure-activity relationships.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.